Histiocytic neoplasms such as Langerhans cell histiocytosis (LCH) and Erdheim–Chester disease (ECD) are characterized by various mutations in the mitogen-activated protein kinase (MAPK) pathway, including BRAF V600E, MAP2K1, and others [1]. Here, MAP2K1 is linked to Langerhans cell histiocytosis.